1
|
Rudman-Melnick V, Adam M, Stowers K, Potter A, Ma Q, Chokshi SM, Vanhoutte D, Valiente-Alandi I, Lindquist DM, Nieman ML, Kofron JM, Chung E, Park JS, Potter SS, Devarajan P. Single-cell sequencing dissects the transcriptional identity of activated fibroblasts and identifies novel persistent distal tubular injury patterns in kidney fibrosis. Sci Rep 2024; 14:439. [PMID: 38172172 PMCID: PMC10764314 DOI: 10.1038/s41598-023-50195-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Accepted: 12/16/2023] [Indexed: 01/05/2024] Open
Abstract
Examining kidney fibrosis is crucial for mechanistic understanding and developing targeted strategies against chronic kidney disease (CKD). Persistent fibroblast activation and tubular epithelial cell (TEC) injury are key CKD contributors. However, cellular and transcriptional landscapes of CKD and specific activated kidney fibroblast clusters remain elusive. Here, we analyzed single cell transcriptomic profiles of two clinically relevant kidney fibrosis models which induced robust kidney parenchymal remodeling. We dissected the molecular and cellular landscapes of kidney stroma and newly identified three distinctive fibroblast clusters with "secretory", "contractile" and "vascular" transcriptional enrichments. Also, both injuries generated failed repair TECs (frTECs) characterized by decline of mature epithelial markers and elevation of stromal and injury markers. Notably, frTECs shared transcriptional identity with distal nephron segments of the embryonic kidney. Moreover, we identified that both models exhibited robust and previously unrecognized distal spatial pattern of TEC injury, outlined by persistent elevation of renal TEC injury markers including Krt8 and Vcam1, while the surviving proximal tubules (PTs) showed restored transcriptional signature. We also found that long-term kidney injuries activated a prominent nephrogenic signature, including Sox4 and Hox gene elevation, which prevailed in the distal tubular segments. Our findings might advance understanding of and targeted intervention in fibrotic kidney disease.
Collapse
Affiliation(s)
- Valeria Rudman-Melnick
- Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229-3039, USA
| | - Mike Adam
- Division Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Kaitlynn Stowers
- Division Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Andrew Potter
- Division Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Qing Ma
- Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229-3039, USA
| | - Saagar M Chokshi
- Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229-3039, USA
| | - Davy Vanhoutte
- Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
- Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA
| | | | - Diana M Lindquist
- Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA
- Department of Radiology, University of Cincinnati, Cincinnati, OH, USA
- Department of Radiology and Medical Imaging, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Michelle L Nieman
- Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, OH, USA
| | - J Matthew Kofron
- Division Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
- Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA
| | - Eunah Chung
- Division of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- Feinberg Cardiovascular and Renal Research Institute, Northwestern University, Chicago, IL, USA
| | - Joo-Seop Park
- Division of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- Feinberg Cardiovascular and Renal Research Institute, Northwestern University, Chicago, IL, USA
| | - S Steven Potter
- Division Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
- Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA
| | - Prasad Devarajan
- Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229-3039, USA.
- Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA.
| |
Collapse
|
2
|
Huo J, Prasad V, Grimes KM, Vanhoutte D, Blair NS, Lin SC, Bround MJ, Bers DM, Molkentin JD. MCUb is an inducible regulator of calcium-dependent mitochondrial metabolism and substrate utilization in muscle. Cell Rep 2023; 42:113465. [PMID: 37976157 PMCID: PMC10842842 DOI: 10.1016/j.celrep.2023.113465] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 09/19/2023] [Accepted: 11/03/2023] [Indexed: 11/19/2023] Open
Abstract
Mitochondria use the electron transport chain to generate high-energy phosphate from oxidative phosphorylation, a process also regulated by the mitochondrial Ca2+ uniporter (MCU) and Ca2+ levels. Here, we show that MCUb, an inhibitor of MCU-mediated Ca2+ influx, is induced by caloric restriction, where it increases mitochondrial fatty acid utilization. To mimic the fasted state with reduced mitochondrial Ca2+ influx, we generated genetically altered mice with skeletal muscle-specific MCUb expression that showed greater fatty acid usage, less fat accumulation, and lower body weight. In contrast, mice lacking Mcub in skeletal muscle showed increased pyruvate dehydrogenase activity, increased muscle malonyl coenzyme A (CoA), reduced fatty acid utilization, glucose intolerance, and increased adiposity. Mechanistically, pyruvate dehydrogenase kinase 4 (PDK4) overexpression in muscle of Mcub-deleted mice abolished altered substrate preference. Thus, MCUb is an inducible control point in regulating skeletal muscle mitochondrial Ca2+ levels and substrate utilization that impacts total metabolic balance.
Collapse
Affiliation(s)
- Jiuzhou Huo
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
| | - Vikram Prasad
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
| | - Kelly M Grimes
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
| | - Davy Vanhoutte
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
| | - N Scott Blair
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
| | - Suh-Chin Lin
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
| | - Michael J Bround
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
| | - Donald M Bers
- Department of Pharmacology, University of California, Davis, Davis, CA 95616, USA
| | - Jeffery D Molkentin
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA.
| |
Collapse
|
3
|
Rudman-Melnick V, Adam M, Stowers K, Potter A, Ma Q, Chokshi SM, Vanhoutte D, Valiente-Alandi I, Lindquist DM, Nieman ML, Kofron JM, Potter SS, Devarajan P. Single-cell sequencing dissects the transcriptional identity of activated fibroblasts and identifies novel persistent distal tubular injury patterns in kidney fibrosis. Res Sq 2023:rs.3.rs-2880248. [PMID: 37293022 PMCID: PMC10246229 DOI: 10.21203/rs.3.rs-2880248/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Examining kidney fibrosis is crucial for mechanistic understanding and developing targeted strategies against chronic kidney disease (CKD). Persistent fibroblast activation and tubular epithelial cell (TEC) injury are key CKD contributors. However, cellular and transcriptional landscapes of CKD and specific activated kidney fibroblast clusters remain elusive. Here, we analyzed single cell transcriptomic profiles of two clinically relevant kidney fibrosis models which induced robust kidney parenchymal remodeling. We dissected the molecular and cellular landscapes of kidney stroma and newly identified three distinctive fibroblast clusters with "secretory", "contractile" and "vascular" transcriptional enrichments. Also, both injuries generated failed repair TECs (frTECs) characterized by decline of mature epithelial markers and elevation of stromal and injury markers. Notably, frTECs shared transcriptional identity with distal nephron segments of the embryonic kidney. Moreover, we identified that both models exhibited robust and previously unrecognized distal spatial pattern of TEC injury, outlined by persistent elevation of renal TEC injury markers including Krt8, while the surviving proximal tubules (PTs) showed restored transcriptional signature. Furthermore, we found that long-term kidney injuries activated a prominent nephrogenic signature, including Sox4 and Hox gene elevation, which prevailed in the distal tubular segments. Our findings might advance understanding of and targeted intervention in fibrotic kidney disease.
Collapse
Affiliation(s)
| | - Mike Adam
- Cincinnati Children's Hospital Medical Center
| | | | | | - Qing Ma
- Cincinnati Children's Hospital Medical Center
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Grimes KM, Prasad V, Huo J, Kuwabara Y, Vanhoutte D, Baldwin TA, Bowers SLK, Johansen AKZ, Sargent MA, Lin SCJ, Molkentin JD. Rpl3l gene deletion in mice reduces heart weight over time. Front Physiol 2023; 14:1054169. [PMID: 36733907 PMCID: PMC9886673 DOI: 10.3389/fphys.2023.1054169] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Accepted: 01/06/2023] [Indexed: 01/18/2023] Open
Abstract
Introduction: The ribosomal protein L3-like (RPL3L) is a heart and skeletal muscle-specific ribosomal protein and paralogue of the more ubiquitously expressed RPL3 protein. Mutations in the human RPL3L gene are linked to childhood cardiomyopathy and age-related atrial fibrillation, yet the function of RPL3L in the mammalian heart remains unknown. Methods and Results: Here, we observed that mouse cardiac ventricles express RPL3 at birth, where it is gradually replaced by RPL3L in adulthood but re-expressed with induction of hypertrophy in adults. Rpl3l gene-deleted mice were generated to examine the role of this gene in the heart, although Rpl3l -/- mice showed no overt changes in cardiac structure or function at baseline or after pressure overload hypertrophy, likely because RPL3 expression was upregulated and maintained in adulthood. mRNA expression analysis and ribosome profiling failed to show differences between the hearts of Rpl3l null and wild type mice in adulthood. Moreover, ribosomes lacking RPL3L showed no differences in localization within cardiomyocytes compared to wild type controls, nor was there an alteration in cardiac tissue ultrastructure or mitochondrial function in adult Rpl3l -/- mice. Similarly, overexpression of either RPL3 or RPL3L with adeno-associated virus -9 in the hearts of mice did not cause discernable pathology. However, by 18 months of age Rpl3l -/- null mice had significantly smaller hearts compared to wild type littermates. Conclusion: Thus, deletion of Rpl3l forces maintenance of RPL3 expression within the heart that appears to fully compensate for the loss of RPL3L, although older Rpl3l -/- mice showed a mild but significant reduction in heart weight.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Jeffery D. Molkentin
- Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, United States
| |
Collapse
|
5
|
Nerger BA, Jones TM, Rose KWJ, Barqué A, Weinbaum JS, Petrie RJ, Chang J, Vanhoutte D, LaDuca K, Hubmacher D, Naba A. The matrix in focus: new directions in extracellular matrix research from the 2021 ASMB hybrid meeting. Biol Open 2022; 11:bio059156. [PMID: 34994383 PMCID: PMC8749129 DOI: 10.1242/bio.059156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
The extracellular matrix (ECM) is a complex assembly of macromolecules that provides both architectural support and molecular signals to cells and modulate their behaviors. Originally considered a passive mechanical structure, decades of research have since demonstrated how the ECM dynamically regulates a diverse set of cellular processes in development, homeostasis, and disease progression. In September 2021, the American Society for Matrix Biology (ASMB) organized a hybrid scientific meeting, integrating in-person and virtual formats, to discuss the latest developments in ECM research. Here, we highlight exciting scientific advances that emerged from the meeting including (1) the use of model systems for fundamental and translation ECM research, (2) ECM-targeting approaches as therapeutic modalities, (3) cell-ECM interactions, and (4) the ECM as a critical component of tissue engineering strategies. In addition, we discuss how the ASMB incorporated mentoring, career development, and diversity, equity, and inclusion initiatives in both virtual and in-person events. Finally, we reflect on the hybrid scientific conference format and how it will help the ASMB accomplish its mission moving forward.
Collapse
Affiliation(s)
- Bryan A. Nerger
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02134, USA
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA
| | - Tia M. Jones
- Department of Biology, Drexel University, Philadelphia, PA 19104, USA
| | - Keron W. J. Rose
- Leni & Peter W. May Department of Orthopedics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Anna Barqué
- Department of Physiology and Biophysics, College of Medicine, University of Illinois at Chicago, Chicago, Illinois 60612, USA
| | - Justin S. Weinbaum
- Department of Bioengineering, Department of Pathology, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA 15219, USA
| | - Ryan J. Petrie
- Department of Biology, Drexel University, Philadelphia, PA 19104, USA
| | - Joan Chang
- Wellcome Centre for Cell-Matrix Research, Division of Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine & Health, University of Manchester, Manchester M13 9PT, UK
| | - Davy Vanhoutte
- Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - Kendra LaDuca
- American Society for Matrix Biology, Rockville, MD 20852, USA
| | - Dirk Hubmacher
- Leni & Peter W. May Department of Orthopedics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Alexandra Naba
- Department of Physiology and Biophysics, College of Medicine, University of Illinois at Chicago, Chicago, Illinois 60612, USA
| |
Collapse
|
6
|
Vanhoutte D, Schips TG, Vo A, Grimes KM, Baldwin TA, Brody MJ, Accornero F, Sargent MA, Molkentin JD. Thbs1 induces lethal cardiac atrophy through PERK-ATF4 regulated autophagy. Nat Commun 2021; 12:3928. [PMID: 34168130 PMCID: PMC8225674 DOI: 10.1038/s41467-021-24215-4] [Citation(s) in RCA: 57] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2019] [Accepted: 05/31/2021] [Indexed: 02/05/2023] Open
Abstract
The thrombospondin (Thbs) family of secreted matricellular proteins are stress- and injury-induced mediators of cellular attachment dynamics and extracellular matrix protein production. Here we show that Thbs1, but not Thbs2, Thbs3 or Thbs4, induces lethal cardiac atrophy when overexpressed. Mechanistically, Thbs1 binds and activates the endoplasmic reticulum stress effector PERK, inducing its downstream transcription factor ATF4 and causing lethal autophagy-mediated cardiac atrophy. Antithetically, Thbs1-/- mice develop greater cardiac hypertrophy with pressure overload stimulation and show reduced fasting-induced atrophy. Deletion of Thbs1 effectors/receptors, including ATF6α, CD36 or CD47 does not diminish Thbs1-dependent cardiac atrophy. However, deletion of the gene encoding PERK in Thbs1 transgenic mice blunts the induction of ATF4 and autophagy, and largely corrects the lethal cardiac atrophy. Finally, overexpression of PERK or ATF4 using AAV9 gene-transfer similarly promotes cardiac atrophy and lethality. Hence, we identified Thbs1-mediated PERK-eIF2α-ATF4-induced autophagy as a critical regulator of cardiomyocyte size in the stressed heart.
Collapse
Affiliation(s)
- Davy Vanhoutte
- Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Tobias G Schips
- Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
- Janssen Pharmaceuticals, Spring House, PA, USA
| | - Alexander Vo
- Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Kelly M Grimes
- Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Tanya A Baldwin
- Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Matthew J Brody
- Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
- Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA
| | - Federica Accornero
- Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
- Department Physiology and Cell Biology, The Ohio State University, Columbus, OH, USA
| | - Michelle A Sargent
- Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Jeffery D Molkentin
- Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
- Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
| |
Collapse
|
7
|
Brody MJ, Vanhoutte D, Bakshi CV, Liu R, Correll RN, Sargent MA, Molkentin JD. Disruption of valosin-containing protein activity causes cardiomyopathy and reveals pleiotropic functions in cardiac homeostasis. J Biol Chem 2019; 294:8918-8929. [PMID: 31006653 DOI: 10.1074/jbc.ra119.007585] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Revised: 04/08/2019] [Indexed: 01/14/2023] Open
Abstract
Valosin-containing protein (VCP), also known as p97, is an ATPase with diverse cellular functions, although the most highly characterized is targeting of misfolded or aggregated proteins to degradation pathways, including the endoplasmic reticulum-associated degradation (ERAD) pathway. However, how VCP functions in the heart has not been carefully examined despite the fact that human mutations in VCP cause Paget disease of bone and frontotemporal dementia, an autosomal dominant multisystem proteinopathy that includes disease in the heart, skeletal muscle, brain, and bone. Here we generated heart-specific transgenic mice overexpressing WT VCP or a VCPK524A mutant with deficient ATPase activity. Transgenic mice overexpressing WT VCP exhibit normal cardiac structure and function, whereas mutant VCP-overexpressing mice develop cardiomyopathy. Mechanistically, mutant VCP-overexpressing hearts up-regulate ERAD complex components and have elevated levels of ubiquitinated proteins prior to manifestation of cardiomyopathy, suggesting dysregulation of ERAD and inefficient clearance of proteins targeted for proteasomal degradation. The hearts of mutant VCP transgenic mice also exhibit profound defects in cardiomyocyte nuclear morphology with increased nuclear envelope proteins and nuclear lamins. Proteomics revealed overwhelming interactions of endogenous VCP with ribosomal, ribosome-associated, and RNA-binding proteins in the heart, and impairment of cardiac VCP activity resulted in aggregation of large ribosomal subunit proteins. These data identify multifactorial functions and diverse mechanisms whereby VCP regulates cardiomyocyte protein and RNA quality control that are critical for cardiac homeostasis, suggesting how human VCP mutations negatively affect the heart.
Collapse
Affiliation(s)
- Matthew J Brody
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229-3039
| | - Davy Vanhoutte
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229-3039
| | - Chinmay V Bakshi
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229-3039
| | - Ruije Liu
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229-3039.,the Department of Biomedical Sciences, Grand Valley State University, Allendale, Michigan 49401, and
| | - Robert N Correll
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229-3039.,the Department of Biological Sciences, University of Alabama, Tuscaloosa, Alabama 35487-0344
| | - Michelle A Sargent
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229-3039
| | - Jeffery D Molkentin
- From the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229-3039, .,the Howard Hughes Medical Institute, Cincinnati, Ohio 45229-3039
| |
Collapse
|
8
|
Schips TG, Vanhoutte D, Vo A, Correll RN, Brody MJ, Khalil H, Karch J, Tjondrokoesoemo A, Sargent MA, Maillet M, Ross RS, Molkentin JD. Thrombospondin-3 augments injury-induced cardiomyopathy by intracellular integrin inhibition and sarcolemmal instability. Nat Commun 2019; 10:76. [PMID: 30622267 PMCID: PMC6325143 DOI: 10.1038/s41467-018-08026-8] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Accepted: 12/03/2018] [Indexed: 01/07/2023] Open
Abstract
Thrombospondins (Thbs) are a family of five secreted matricellular glycoproteins in vertebrates that broadly affect cell-matrix interaction. While Thbs4 is known to protect striated muscle from disease by enhancing sarcolemmal stability through increased integrin and dystroglycan attachment complexes, here we show that Thbs3 antithetically promotes sarcolemmal destabilization by reducing integrin function, augmenting disease-induced decompensation. Deletion of Thbs3 in mice enhances integrin membrane expression and membrane stability, protecting the heart from disease stimuli. Transgene-mediated overexpression of α7β1D integrin in the heart ameliorates the disease predisposing effects of Thbs3 by augmenting sarcolemmal stability. Mechanistically, we show that mutating Thbs3 to contain the conserved RGD integrin binding domain normally found in Thbs4 and Thbs5 now rescues the defective expression of integrins on the sarcolemma. Thus, Thbs proteins mediate the intracellular processing of integrin plasma membrane attachment complexes to regulate the dynamics of cellular remodeling and membrane stability.
Collapse
Affiliation(s)
- Tobias G Schips
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA
| | - Davy Vanhoutte
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA
| | - Alexander Vo
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA
| | - Robert N Correll
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA
| | - Matthew J Brody
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA
| | - Hadi Khalil
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA
| | - Jason Karch
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA
- Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA
| | - Andoria Tjondrokoesoemo
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA
| | - Michelle A Sargent
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA
| | - Marjorie Maillet
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA
| | - Robert S Ross
- Division of Cardiology, Department of Medicine, University of California at San Diego School of Medicine, La Jolla, CA, 92093, USA
| | - Jeffery D Molkentin
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.
- Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA.
| |
Collapse
|
9
|
Brody MJ, Vanhoutte D, Viswanathan MC, Nguyen T, Maillet M, York AJ, Sargent MA, Cammarato A, Molkentin JD. Abstract 548: Evolutionarily Conserved Functions for Valosin Containing Protein (VCP) in Cardiac and Skeletal Muscle Reveal Mechanistic Insights into Multisystem Proteinopathy. Circ Res 2018. [DOI: 10.1161/res.123.suppl_1.548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Valosin Containing Protein (VCP)/p97 is a AAA-ATPase with functions in vast cellular protein quality control processes, including targeting of misfolded or aggregated proteins for degradation by the ubiquitin proteasome system and autophagy. Mutations in VCP cause a multisystem degenerative proteinopathy disorder that includes pathologies of the nervous system, skeletal muscle, bone, and heart. However, the molecular function of VCP in myocytes is unknown. We generated cardiomyocyte-specific transgenic mice overexpressing wildtype VCP or a VCP
K524A
mutant with deficient ATPase activity. Mice overexpressing wildtype VCP exhibit normal cardiac structure and function while mutant VCP overexpressing mice develop cardiomyopathy and have elevated levels of ubiquitinated proteins in the heart. Additionally, we generated transgenic flies overexpressing wildtype VCP or VCP
K524A
in muscle. Flies overexpressing the VCP ATPase-deficient mutant have reduced flight ability at two days of age and are unable to fly at seven days of age, suggesting conserved indispensable homeostatic functions for VCP in heart and skeletal muscle. Moreover, mouse hearts and
Drosophila
indirect flight muscle overexpressing the ATPase-deficient VCP mutant exhibit profound ultrastructural abnormalities consistent with dysregulation of proteostasis. Extensive proteomics in
Drosophila
and in mouse heart identified conserved interactions of VCP with protein complexes that suggest unique functions for VCP in regulating novel quality control pathways in muscle. These data and novel regulatory relationships will be presented, which implicate important and evolutionarily conserved functions for VCP and suggest molecular mechanisms that underlie the molecular etiology of multisystem proteinopathy disorders.
Collapse
Affiliation(s)
| | | | | | | | | | - Allen J York
- Cincinnati Childrens Hosp, Howard Hughes Med Institute, Cincinnati, OH
| | | | | | | |
Collapse
|
10
|
Schips TG, Vanhoutte D, Brody M, Correll N, Tjondrokoesoemo A, Sargent M, Maillet M, Molkentin JD. Abstract 407: Divergent Functions of Thrombospondin Genes in Mammals. Circ Res 2017. [DOI: 10.1161/res.121.suppl_1.407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Thrombospondin (Thbs) proteins are multidomain, matricellular proteins comprised of 5 genes that each share similar domains and have been largely ascribed the same functional characteristics. The Thbs protein family is divided in 2 subgroups based on multimerization as trimers, (group A: Thbs1 and 2), or as pentamers (group B: Thbs3, 4 and 5). Thbs proteins modulate various aspects of cell- matrix interactions. Thbs1 and 2 can also alter angiogenesis and modulate MMP- as well as TGF beta activity. More recently, we have shown that they can also serve an intracellular chaperone function along the secretory pathway in response to ER stress (Lynch et. al. Cell 2012). The overall aim of this study is to functionally compare the two Thbs subgroups and elucidate their involvement in cardiac homeostasis and disease. Hence we analyzed gain and loss of function mouse models for Thbs1 as a representative of group A and Thbs3 for group B. Our overall conclusion was that Thbs4 serves a protective function in the heart while Thbs1 and Thbs3 are either overtly maladaptive or they predispose to worsening heart disease with injury stimulus. Taken together, this is the first study comparing Thbs subfamilies, unraveling previously unrecognized functions of Thbs1 and 3 in the mammalian heart, which appears to oppose the protective function of Thbs4.
Collapse
|
11
|
Vanhoutte D, Schips TG, Kwong JQ, Davis J, Tjondrokoesoemo A, Brody MJ, Sargent MA, Kanisicak O, Yi H, Gao QQ, Rabinowitz JE, Volk T, McNally EM, Molkentin JD. Thrombospondin expression in myofibers stabilizes muscle membranes. eLife 2016; 5. [PMID: 27669143 PMCID: PMC5063588 DOI: 10.7554/elife.17589] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Accepted: 09/21/2016] [Indexed: 12/26/2022] Open
Abstract
Skeletal muscle is highly sensitive to mutations in genes that participate in membrane stability and cellular attachment, which often leads to muscular dystrophy. Here we show that Thrombospondin-4 (Thbs4) regulates skeletal muscle integrity and its susceptibility to muscular dystrophy through organization of membrane attachment complexes. Loss of the Thbs4 gene causes spontaneous dystrophic changes with aging and accelerates disease in 2 mouse models of muscular dystrophy, while overexpression of mouse Thbs4 is protective and mitigates dystrophic disease. In the myofiber, Thbs4 selectively enhances vesicular trafficking of dystrophin-glycoprotein and integrin attachment complexes to stabilize the sarcolemma. In agreement, muscle-specific overexpression of Drosophila Tsp or mouse Thbs4 rescues a Drosophila model of muscular dystrophy with augmented membrane residence of βPS integrin. This functional conservation emphasizes the fundamental importance of Thbs' as regulators of cellular attachment and membrane stability and identifies Thbs4 as a potential therapeutic target for muscular dystrophy.
Collapse
Affiliation(s)
- Davy Vanhoutte
- Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, United States
| | - Tobias G Schips
- Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, United States
| | - Jennifer Q Kwong
- Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, United States
| | - Jennifer Davis
- Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, United States
| | - Andoria Tjondrokoesoemo
- Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, United States
| | - Matthew J Brody
- Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, United States
| | - Michelle A Sargent
- Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, United States
| | - Onur Kanisicak
- Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, United States
| | - Hong Yi
- Robert P. Apkarian Integrated Electron Microscopy Core, Emory University, Atlanta, United States
| | - Quan Q Gao
- Center for Genetic Medicine, Northwestern University, Chicago, United States
| | | | - Talila Volk
- Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
| | - Elizabeth M McNally
- Center for Genetic Medicine, Northwestern University, Chicago, United States
| | - Jeffery D Molkentin
- Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, United States.,Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, United States
| |
Collapse
|
12
|
Wallner M, Duran JM, Mohsin S, Troupes CD, Vanhoutte D, Borghetti G, Vagnozzi RJ, Gross P, Yu D, Trappanese DM, Kubo H, Toib A, Sharp TE, Harper SC, Volkert MA, Starosta T, Feldsott EA, Berretta RM, Wang T, Barbe MF, Molkentin JD, Houser SR. Acute Catecholamine Exposure Causes Reversible Myocyte Injury Without Cardiac Regeneration. Circ Res 2016; 119:865-79. [PMID: 27461939 DOI: 10.1161/circresaha.116.308687] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Accepted: 07/26/2016] [Indexed: 12/28/2022]
Abstract
RATIONALE Catecholamines increase cardiac contractility, but exposure to high concentrations or prolonged exposures can cause cardiac injury. A recent study demonstrated that a single subcutaneous injection of isoproterenol (ISO; 200 mg/kg) in mice causes acute myocyte death (8%-10%) with complete cardiac repair within a month. Cardiac regeneration was via endogenous cKit(+) cardiac stem cell-mediated new myocyte formation. OBJECTIVE Our goal was to validate this simple injury/regeneration system and use it to study the biology of newly forming adult cardiac myocytes. METHODS AND RESULTS C57BL/6 mice (n=173) were treated with single injections of vehicle, 200 or 300 mg/kg ISO, or 2 daily doses of 200 mg/kg ISO for 6 days. Echocardiography revealed transiently increased systolic function and unaltered diastolic function 1 day after single ISO injection. Single ISO injections also caused membrane injury in ≈10% of myocytes, but few of these myocytes appeared to be necrotic. Circulating troponin I levels after ISO were elevated, further documenting myocyte damage. However, myocyte apoptosis was not increased after ISO injury. Heart weight to body weight ratio and fibrosis were also not altered 28 days after ISO injection. Single- or multiple-dose ISO injury was not associated with an increase in the percentage of 5-ethynyl-2'-deoxyuridine-labeled myocytes. Furthermore, ISO injections did not increase new myocytes in cKit(+/Cre)×R-GFP transgenic mice. CONCLUSIONS A single dose of ISO causes injury in ≈10% of the cardiomyocytes. However, most of these myocytes seem to recover and do not elicit cKit(+) cardiac stem cell-derived myocyte regeneration.
Collapse
Affiliation(s)
- Markus Wallner
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Jason M Duran
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Sadia Mohsin
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Constantine D Troupes
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Davy Vanhoutte
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Giulia Borghetti
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Ronald J Vagnozzi
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Polina Gross
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Daohai Yu
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Danielle M Trappanese
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Hajime Kubo
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Amir Toib
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Thomas E Sharp
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Shavonn C Harper
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Michael A Volkert
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Timothy Starosta
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Eric A Feldsott
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Remus M Berretta
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Tao Wang
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Mary F Barbe
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Jeffrey D Molkentin
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.)
| | - Steven R Houser
- From the Cardiovascular Research Center (M.W., J.M.D., S.M., C.D.T., G.B., P.G., D.M.T., H.K., T.E.S., S.C.H., M.A.V., T.S., E.A.F., R.M.B., T.W., S.R.H.), Department of Clinical Sciences (D.Y.), and Department of Anatomy and Cell Biology (M.F.B.), Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH (D.V., R.J.V., J.D.M.); Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA (A.T.); Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH (J.D.M.); and Department of Internal Medicine, University of California San Diego Medical Center, San Diego, CA (J.M.D.).
| |
Collapse
|
13
|
Tjondrokoesoemo A, Schips TG, Sargent MA, Vanhoutte D, Kanisicak O, Prasad V, Lin SCJ, Maillet M, Molkentin JD. Cathepsin S Contributes to the Pathogenesis of Muscular Dystrophy in Mice. J Biol Chem 2016; 291:9920-8. [PMID: 26966179 DOI: 10.1074/jbc.m116.719054] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Indexed: 11/06/2022] Open
Abstract
Duchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by mutations in the gene encoding dystrophin. Loss of dystrophin protein compromises the stability of the sarcolemma membrane surrounding each muscle cell fiber, leading to membrane ruptures and leakiness that induces myofiber necrosis, a subsequent inflammatory response, and progressive tissue fibrosis with loss of functional capacity. Cathepsin S (Ctss) is a cysteine protease that is actively secreted in areas of tissue injury and ongoing inflammation, where it participates in extracellular matrix remodeling and healing. Here we show significant induction of Ctss expression and proteolytic activity following acute muscle injury or in muscle from mdx mice, a model of DMD. To examine the functional ramifications associated with greater Ctss expression, the Ctss gene was deleted in the mdx genetic background, resulting in protection from muscular dystrophy pathogenesis that included reduced myofiber turnover and histopathology, reduced fibrosis, and improved running capacity. Mechanistically, deletion of the Ctss gene in the mdx background significantly increased myofiber sarcolemmal membrane stability with greater expression and membrane localization of utrophin, integrins, and β-dystroglycan, which anchor the membrane to the basal lamina and underlying cytoskeletal proteins. Consistent with these results, skeletal muscle-specific transgenic mice overexpressing Ctss showed increased myofiber necrosis, muscle histopathology, and a functional deficit reminiscent of muscular dystrophy. Hence, Ctss induction during muscular dystrophy is a pathologic event that partially underlies disease pathogenesis, and its inhibition might serve as a new therapeutic strategy in DMD.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Jeffery D Molkentin
- From the Department of Pediatrics and Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229
| |
Collapse
|
14
|
Putz L, Muschart X, Borgers G, Keersebick E, Jennes S, Vanhoutte D, Van der Vorst S. Tracheal damage. B-ENT 2016; Suppl 26:87-102. [PMID: 29558579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023] Open
Abstract
Tracheal damage. Blunt/penetrating trauma and inhalation injuries to the trachea can result in acute airway compromise, with life-threatening implications. Early assessment, identification, and prompt and appropriate management are of paramount importance in order to reduce patient morbidity and mortality. Signs and symptoms of these injuries are specific and sometimes subtle, and their seriousness may be obscured by other injuries. Diagnosis can therefore be challenging, requiring a high index of suspicion. Indeed, diagnosis and treatment are often delayed, resulting in attempted surgical repair months or even years after injury. Laryngoscopy, flexible and/or rigid bronchoscopy and computed tomography of the chest are the procedures of choice for a definitive diagnosis. Airway control and appropriate ventilation represent the key aspects of emergency management. Definitive treatment depends on the site and the extent of injury. Surgery, involving primary repair with direct suture or resection and end-to-end anastomosis, is the treatment of choice for patients suffering from tracheal injuries. A conservative approach must be considered for the paediatric population and selected patients with mainly iatrogenic damage. We present a review of the incidence, mechanisms of injury, clinical presentations, diagnosis, initial airway management, anaesthetic considerations and definitive treatment in the case of tracheal damage from blunt/penetrating trauma and inhalation injuries.
Collapse
MESH Headings
- Airway Management
- Anticoagulants/therapeutic use
- Bronchodilator Agents/therapeutic use
- Burns, Inhalation/complications
- Burns, Inhalation/diagnosis
- Burns, Inhalation/therapy
- Emergency Medical Services
- Emergency Service, Hospital
- Endoscopy
- Expectorants/therapeutic use
- Humans
- Hyperbaric Oxygenation
- Intubation, Intratracheal/adverse effects
- Respiration, Artificial
- Trachea/diagnostic imaging
- Trachea/injuries
- Trachea/surgery
- Wounds, Nonpenetrating/complications
- Wounds, Nonpenetrating/therapy
- Wounds, Penetrating/complications
- Wounds, Penetrating/therapy
Collapse
|
15
|
Schwanekamp JA, Lorts A, Vagnozzi RJ, Vanhoutte D, Molkentin JD. Deletion of Periostin Protects Against Atherosclerosis in Mice by Altering Inflammation and Extracellular Matrix Remodeling. Arterioscler Thromb Vasc Biol 2015; 36:60-8. [PMID: 26564821 DOI: 10.1161/atvbaha.115.306397] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Accepted: 10/29/2015] [Indexed: 12/20/2022]
Abstract
OBJECTIVE Periostin is a secreted protein that can alter extracellular matrix remodeling in response to tissue injury. However, the functional role of periostin in the development of atherosclerotic plaques has yet to be described despite its observed induction in diseased vessels and presence in the serum. APPROACH AND RESULTS Hyperlipidemic, apolipoprotein E-null mice (ApoE(-/) (-)) were crossed with periostin (Postn(-/-)) gene-deleted mice and placed on a high-fat diet for 6 or 14 weeks to induce atherosclerosis. En face analysis of aortas showed significantly decreased lesion areas of ApoE(-/-) Postn(-/-) mice compared with ApoE(-/-) mice, as well as a reduced inflammatory response with less macrophage content. Moreover, diseased aortas from ApoE(-/-) Postn(-/-) mice displayed a disorganized extracellular matrix with less collagen cross linking and smaller fibrotic caps, as well as increased matrix metalloproteinase-2, metalloproteinase-13, and procollagen-lysine, 2-oxoglutarate 5-dioxygenase-1 mRNA expression. Furthermore, the loss of periostin was associated with a switch in vascular smooth muscle cells toward a more proliferative and synthetic phenotype. Mechanistically, the loss of periostin reduced macrophage recruitment by transforming growth factor-β in cellular migration assays. CONCLUSIONS These are the first genetic data detailing the function of periostin as a regulator of atherosclerotic lesion formation and progression. The data suggest that periostin could be a therapeutic target for atherosclerotic plaque formation through modulation of the immune response and extracellular matrix remodeling.
Collapse
MESH Headings
- Animals
- Aorta, Thoracic/immunology
- Aorta, Thoracic/metabolism
- Aorta, Thoracic/pathology
- Aortic Diseases/genetics
- Aortic Diseases/immunology
- Aortic Diseases/metabolism
- Aortic Diseases/pathology
- Aortic Diseases/prevention & control
- Apolipoproteins E/deficiency
- Apolipoproteins E/genetics
- Atherosclerosis/genetics
- Atherosclerosis/immunology
- Atherosclerosis/metabolism
- Atherosclerosis/pathology
- Atherosclerosis/prevention & control
- Cell Adhesion Molecules/deficiency
- Cell Adhesion Molecules/genetics
- Cell Movement
- Cell Proliferation
- Cells, Cultured
- Collagen/metabolism
- Diet, High-Fat
- Disease Models, Animal
- Disease Progression
- Extracellular Matrix/metabolism
- Gene Deletion
- Gene Expression Regulation
- Inflammation/genetics
- Inflammation/immunology
- Inflammation/metabolism
- Inflammation/pathology
- Inflammation/prevention & control
- Macrophages/metabolism
- Mice, Inbred C57BL
- Mice, Knockout
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- Myocytes, Smooth Muscle/metabolism
- Myocytes, Smooth Muscle/pathology
- Phenotype
- Plaque, Atherosclerotic
- RNA, Messenger/metabolism
- Signal Transduction
- Time Factors
- Vascular Remodeling
Collapse
Affiliation(s)
- Jennifer A Schwanekamp
- From the Department of Pediatrics (J.A.S., A.L., R.J.V., D.V., J.D.M.) and Howard Hughes Medical Institute (J.D.M.), Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH
| | - Angela Lorts
- From the Department of Pediatrics (J.A.S., A.L., R.J.V., D.V., J.D.M.) and Howard Hughes Medical Institute (J.D.M.), Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH
| | - Ronald J Vagnozzi
- From the Department of Pediatrics (J.A.S., A.L., R.J.V., D.V., J.D.M.) and Howard Hughes Medical Institute (J.D.M.), Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH
| | - Davy Vanhoutte
- From the Department of Pediatrics (J.A.S., A.L., R.J.V., D.V., J.D.M.) and Howard Hughes Medical Institute (J.D.M.), Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH
| | - Jeffery D Molkentin
- From the Department of Pediatrics (J.A.S., A.L., R.J.V., D.V., J.D.M.) and Howard Hughes Medical Institute (J.D.M.), Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH.
| |
Collapse
|
16
|
Schips T, Vanhoutte D. Marfan syndrome and aortic aneurysm: Lysyl oxidases to the rescue? J Mol Cell Cardiol 2015; 86:9-11. [DOI: 10.1016/j.yjmcc.2015.06.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2015] [Revised: 06/16/2015] [Accepted: 06/18/2015] [Indexed: 01/01/2023]
|
17
|
Van Aelst LN, Voss S, Carai P, Van Leeuwen R, Vanhoutte D, Sanders-van Wijk S, Eurlings L, Swinnen M, Verheyen FK, Verbeken E, Nef H, Troidl C, Cook SA, Brunner-La Rocca HP, Möllmann H, Papageorgiou AP, Heymans S. Osteoglycin Prevents Cardiac Dilatation and Dysfunction After Myocardial Infarction Through Infarct Collagen Strengthening. Circ Res 2015; 116:425-36. [DOI: 10.1161/circresaha.116.304599] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Rationale:
To maintain cardiac mechanical and structural integrity after an ischemic insult, profound alterations occur within the extracellular matrix. Osteoglycin is a small leucine-rich proteoglycan previously described as a marker of cardiac hypertrophy.
Objective:
To establish whether osteoglycin may play a role in cardiac integrity and function after myocardial infarction (MI).
Methods and Results:
Osteoglycin expression is associated with collagen deposition and scar formation in mouse and human MI. Absence of osteoglycin in mice resulted in significantly increased rupture-related mortality with tissue disruption, intramyocardial bleeding, and increased cardiac dysfunction, despite equal infarct sizes. Surviving osteoglycin null mice had greater infarct expansion in comparison with wild-type mice because of impaired collagen fibrillogenesis and maturation in the infarcts as revealed by electron microscopy and collagen polarization. Absence of osteoglycin did not affect cardiomyocyte hypertrophy in the remodeling remote myocardium. In cultured fibroblasts, osteoglycin knockdown or supplementation did not alter transforming growth factor-β signaling. Adenoviral overexpression of osteoglycin in wild-type mice significantly improved collagen quality, thereby blunting cardiac dilatation and dysfunction after MI. In osteoglycin null mice, adenoviral overexpression of osteoglycin was unable to prevent rupture-related mortality because of insufficiently restoring osteoglycin protein levels in the heart. Finally, circulating osteoglycin levels in patients with heart failure were significantly increased in the patients with a previous history of MI compared with those with nonischemic heart failure and correlated with survival, left ventricular volumes, and other markers of fibrosis.
Conclusions:
Increased osteoglycin expression in the infarct scar promotes proper collagen maturation and protects against cardiac disruption and adverse remodeling after MI. In human heart failure, osteoglycin is a promising biomarker for ischemic heart failure.
Collapse
Affiliation(s)
- Lucas N.L. Van Aelst
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Sandra Voss
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Paolo Carai
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Rick Van Leeuwen
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Davy Vanhoutte
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Sandra Sanders-van Wijk
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Luc Eurlings
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Melissa Swinnen
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Fons K. Verheyen
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Eric Verbeken
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Holger Nef
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Christian Troidl
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Stuart A. Cook
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Hans-Peter Brunner-La Rocca
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Helge Möllmann
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Anna-Pia Papageorgiou
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| | - Stephane Heymans
- From the Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Catholic University of Leuven, Leuven, Belgium (L.N.L.V.A., P.C., A.-P.P., S.H.); Department of Cardiology (L.N.L.V.A., M.S.) and Department of Pathology (E.V.), University Hospitals Leuven, Leuven, Belgium; Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany (S.V., H.N., C.T., H.M.); Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), University Hospital
| |
Collapse
|
18
|
Murdoch CE, Chaubey S, Zeng L, Yu B, Ivetic A, Walker SJ, Vanhoutte D, Heymans S, Grieve DJ, Cave AC, Brewer AC, Zhang M, Shah AM. Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition. J Am Coll Cardiol 2014; 63:2734-41. [PMID: 24681145 DOI: 10.1016/j.jacc.2014.02.572] [Citation(s) in RCA: 144] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2013] [Revised: 02/22/2014] [Accepted: 02/25/2014] [Indexed: 12/15/2022]
Abstract
OBJECTIVES This study sought to investigate the effect of endothelial dysfunction on the development of cardiac hypertrophy and fibrosis. BACKGROUND Endothelial dysfunction accompanies cardiac hypertrophy and fibrosis, but its contribution to these conditions is unclear. Increased nicotinamide adenine dinucleotide phosphate oxidase-2 (NOX2) activation causes endothelial dysfunction. METHODS Transgenic mice with endothelial-specific NOX2 overexpression (TG mice) and wild-type littermates received long-term angiotensin II (AngII) infusion (1.1 mg/kg/day, 2 weeks) to induce hypertrophy and fibrosis. RESULTS TG mice had systolic hypertension and hypertrophy similar to those seen in wild-type mice but developed greater cardiac fibrosis and evidence of isolated left ventricular diastolic dysfunction (p < 0.05). TG myocardium had more inflammatory cells and VCAM-1-positive vessels than did wild-type myocardium after AngII treatment (both p < 0.05). TG microvascular endothelial cells (ECs) treated with AngII recruited 2-fold more leukocytes than did wild-type ECs in an in vitro adhesion assay (p < 0.05). However, inflammatory cell NOX2 per se was not essential for the profibrotic effects of AngII. TG showed a higher level of endothelial-mesenchymal transition (EMT) than did wild-type mice after AngII infusion. In cultured ECs treated with AngII, NOX2 enhanced EMT as assessed by the relative expression of fibroblast versus endothelial-specific markers. CONCLUSIONS AngII-induced endothelial NOX2 activation has profound profibrotic effects in the heart in vivo that lead to a diastolic dysfunction phenotype. Endothelial NOX2 enhances EMT and has proinflammatory effects. This may be an important mechanism underlying cardiac fibrosis and diastolic dysfunction during increased renin-angiotensin activation.
Collapse
Affiliation(s)
- Colin E Murdoch
- King's College London British Heart Foundation Centre of Excellence, Cardiovascular Division, London, United Kingdom
| | - Sanjay Chaubey
- King's College London British Heart Foundation Centre of Excellence, Cardiovascular Division, London, United Kingdom
| | - Lingfang Zeng
- King's College London British Heart Foundation Centre of Excellence, Cardiovascular Division, London, United Kingdom
| | - Bin Yu
- King's College London British Heart Foundation Centre of Excellence, Cardiovascular Division, London, United Kingdom
| | - Aleksander Ivetic
- King's College London British Heart Foundation Centre of Excellence, Cardiovascular Division, London, United Kingdom
| | - Simon J Walker
- King's College London British Heart Foundation Centre of Excellence, Cardiovascular Division, London, United Kingdom
| | - Davy Vanhoutte
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands
| | - Stephane Heymans
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands
| | - David J Grieve
- King's College London British Heart Foundation Centre of Excellence, Cardiovascular Division, London, United Kingdom
| | - Alison C Cave
- King's College London British Heart Foundation Centre of Excellence, Cardiovascular Division, London, United Kingdom
| | - Alison C Brewer
- King's College London British Heart Foundation Centre of Excellence, Cardiovascular Division, London, United Kingdom
| | - Min Zhang
- King's College London British Heart Foundation Centre of Excellence, Cardiovascular Division, London, United Kingdom
| | - Ajay M Shah
- King's College London British Heart Foundation Centre of Excellence, Cardiovascular Division, London, United Kingdom.
| |
Collapse
|
19
|
Rainer PP, Hao S, Vanhoutte D, Lee DI, Koitabashi N, Molkentin JD, Kass DA. Cardiomyocyte-specific transforming growth factor β suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction. Circ Res 2014; 114:1246-57. [PMID: 24573206 DOI: 10.1161/circresaha.114.302653] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
RATIONALE Wound healing after myocardial infarction involves a highly regulated inflammatory response that is initiated by the appearance of neutrophils to clear out dead cells and matrix debris. Neutrophil infiltration is controlled by multiple secreted factors, including the master regulator transforming growth factor β (TGFβ). Broad inhibition of TGFβ early postinfarction has worsened post-myocardial infarction remodeling; however, this signaling displays potent cell specificity, and targeted suppression particularly in the myocyte could be beneficial. OBJECTIVE Our aims were to test the hypothesis that targeted suppression of myocyte TGFβ signaling ameliorates postinfarct remodeling and inflammatory modulation and to identify mechanisms by which this may be achieved. METHODS AND RESULTS Mice with TGFβ receptor-coupled signaling genetically suppressed only in cardiac myocytes (conditional TGFβ receptor 1 or 2 knockout) displayed marked declines in neutrophil recruitment and accompanying metalloproteinase 9 activation after infarction and were protected against early-onset mortality due to wall rupture. This is a cell-specific effect, because broader inhibition of TGFβ signaling led to 100% early mortality due to rupture. Rather than by altering fibrosis or reducing the generation of proinflammatory cytokines/chemokines, myocyte-selective TGFβ inhibition augmented the synthesis of a constellation of highly protective cardiokines. These included thrombospondin 4 with associated endoplasmic reticulum stress responses, interleukin-33, follistatin-like 1, and growth and differentiation factor 15, which is an inhibitor of neutrophil integrin activation and tissue migration. CONCLUSIONS These data reveal a novel role of myocyte TGFβ signaling as a potent regulator of protective cardiokine and neutrophil-mediated infarct remodeling.
Collapse
Affiliation(s)
- Peter P Rainer
- From the Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD (P.P.R., S.H., D.I.L., N.K., D.A.K.); Division of Cardiology, Medical University of Graz, Austria (P.P.R.); Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH (D.V., J.D.M.); Howard Hughes Medical Institute, University of Cincinnati, Cincinnati, OH (J.D.M.); and Department of Medicine and Biological Science, Gunma University Graduate School of Medicine, Gunma, Japan (N.K.)
| | | | | | | | | | | | | |
Collapse
|
20
|
Rienks M, Vanhoutte D, Van Teeffelen J, Carai P, Eskens B, Papageorgiou A, Heymans S. Matrix protein Osteonectin (SPARC) reduces inflammation and mortality during viral myocarditis. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht311.5868] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Papageorgiou A, Rienks M, Vanhoutte D, Verhesen W, Carai P, Vandendriessche T, Chuah M, Heymans S. Osteonectin protects against adverse cardiac inflammation during viral myocarditis. FASEB J 2013. [DOI: 10.1096/fasebj.27.1_supplement.1128.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Anna Papageorgiou
- Maastricht UniversityMaastrichtNetherlands
- University LeuvenLeuvenBelgium
| | | | - Davy Vanhoutte
- Cincinnati Children's Hospital Medical CenterCincinnatiOH
| | | | - Paolo Carai
- Maastricht UniversityMaastrichtNetherlands
- University LeuvenLeuvenBelgium
| | | | | | - Stephane Heymans
- Maastricht UniversityMaastrichtNetherlands
- University LeuvenLeuvenBelgium
| |
Collapse
|
22
|
Vanhoutte D, van Almen GC, Van Aelst LNL, Van Cleemput J, Droogné W, Jin Y, Van de Werf F, Carmeliet P, Vanhaecke J, Papageorgiou AP, Heymans S. Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allograft rejection. Eur Heart J 2012; 34:1930-41. [PMID: 23139380 PMCID: PMC4051259 DOI: 10.1093/eurheartj/ehs375] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
Aims The cardiac extracellular matrix is highly involved in regulating inflammation, remodelling, and function of the heart. Whether matrix alterations relate to the degree of inflammation, fibrosis, and overall rejection in the human transplanted heart remained, until now, unknown. Methods and results Expression of matricellular proteins, proteoglycans, and metalloproteinases (MMPs) and their inhibitors (TIMPs) were investigated in serial endomyocardial biopsies (n = 102), in a cohort of 39 patients within the first year after cardiac transplantation. Out of 15 matrix-related proteins, intragraft transcript and protein levels of syndecan-1 and MMP-9 showed a strong association with the degree of cardiac allograft rejection (CAR), the expression of pro-inflammatory cytokines tumour necrosis factor (TNF)-α, interleukin (IL)-6 and transforming growth factor (TGF)-β, and with infiltrating CD3+T-cells and CD68+monocytes. In addition, SPARC, CTGF, TSP-2, MMP-14, TIMP-1, Testican-1, TSP-1, Syndecan-1, MMP-2, -9, and -14, as well as IL-6 and TGF-β transcript levels and inflammatory infiltrates all strongly relate to collagen expression in the transplanted heart. More importantly, receiver operating characteristic curve analysis demonstrated that syndecan-1 and MMP-9 transcript levels had the highest area under the curve (0.969 and 0.981, respectively), thereby identifying both as a potential decision-making tool to discriminate rejecting from non-rejecting hearts. Conclusion Out of 15 matrix-related proteins, we identified synd-1 and MMP-9 intragraft transcript levels of as strong predictors of human CAR. In addition, a multitude of non-structural matrix-related proteins closely associate with collagen expression in the transplanted heart. Therefore, we are convinced that these findings deserve further investigation and are likely to be of clinical value to prevent human CAR.
Collapse
Affiliation(s)
- Davy Vanhoutte
- Cardiovascular Diseases, University Hospitals Leuven, and Department of Cardiovascular Sciences, KU Leuven, Belgium.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Lynch JM, Maillet M, Vanhoutte D, Schloemer A, Sargent MA, Blair NS, Lynch KA, Okada T, Aronow BJ, Osinska H, Prywes R, Lorenz JN, Mori K, Lawler J, Robbins J, Molkentin JD. A thrombospondin-dependent pathway for a protective ER stress response. Cell 2012; 149:1257-68. [PMID: 22682248 DOI: 10.1016/j.cell.2012.03.050] [Citation(s) in RCA: 155] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2011] [Revised: 02/03/2012] [Accepted: 03/20/2012] [Indexed: 12/14/2022]
Abstract
Thrombospondin (Thbs) proteins are induced in sites of tissue damage or active remodeling. The endoplasmic reticulum (ER) stress response is also prominently induced with disease where it regulates protein production and resolution of misfolded proteins. Here we describe a function for Thbs as ER-resident effectors of an adaptive ER stress response. Thbs4 cardiac-specific transgenic mice were protected from myocardial injury, whereas Thbs4(-/-) mice were sensitized to cardiac maladaptation. Thbs induction produced a unique profile of adaptive ER stress response factors and expansion of the ER and downstream vesicles. Thbs bind the ER lumenal domain of activating transcription factor 6α (Atf6α) to promote its nuclear shuttling. Thbs4(-/-) mice showed blunted activation of Atf6α and other ER stress-response factors with injury, and Thbs4-mediated protection was lost upon Atf6α deletion. Hence, Thbs can function inside the cell during disease remodeling to augment ER function and protect through a mechanism involving regulation of Atf6α.
Collapse
Affiliation(s)
- Jeffrey M Lynch
- Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, OH 45247, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Heymans S, Rienks M, Vanhoutte D, Swinnen M, Westermann D, VandenDriessche T, Lijnen R, Schroen B, Papageorgiou A, Carmeliet P. The matricellular proteins thrombospondin‐2, osteonectin and osteoglycin modulate cardiac inflammation, injury and function during viral myocarditis. FASEB J 2012. [DOI: 10.1096/fasebj.26.1_supplement.1060.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Stephane Heymans
- CardiologyCentre for Heart Failure ResearchMaastricht UniversityMaastrichtNetherlands
- Cardiovascular DepartmentUniversity of LeuvenLeuvenBelgium
| | - Marieke Rienks
- CardiologyCentre for Heart Failure ResearchMaastricht UniversityMaastrichtNetherlands
| | - Davy Vanhoutte
- Cardiovascular DepartmentUniversity of LeuvenLeuvenBelgium
| | | | | | | | - Roger Lijnen
- Cardiovascular DepartmentUniversity of LeuvenLeuvenBelgium
| | - Blanche Schroen
- CardiologyCentre for Heart Failure ResearchMaastricht UniversityMaastrichtNetherlands
| | - Anna Papageorgiou
- CardiologyCentre for Heart Failure ResearchMaastricht UniversityMaastrichtNetherlands
| | | |
Collapse
|
25
|
Papageorgiou AP, Swinnen M, Vanhoutte D, VandenDriessche T, Chuah M, Lindner D, Verhesen W, de Vries B, D'hooge J, Lutgens E, Westermann D, Carmeliet P, Heymans S. Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells. Cardiovasc Res 2012; 94:115-24. [DOI: 10.1093/cvr/cvs077] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
26
|
Vanhoutte D, Van Berlo J, York AJ, Zheng Y, Molkentin JD. Abstract P189: RhoA Functions as an Antihypertrophic Switch in the Mouse Heart. Circ Res 2011. [DOI: 10.1161/res.109.suppl_1.ap189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background.
Small GTPase RhoA has been previously implicated as an important signaling effector within the cardiomyocyte. However, recent studies have challenged the hypothesized role of RhoA as an effector of cardiac hypertrophy. Therefore, this study examined the
in vivo
role of RhoA in the development of pathological cardiac hypertrophy.
Methods and results
. Endogenous RhoA protein expression and activity levels (GTP-bound) in wild-type hearts were significantly increased after pressure overload induced by transverse aortic constriction (TAC). To investigate the necessity of RhoA within the adult heart, RhoA-LoxP-targeted (RhoA
flx/flx
) mice were crossed with transgenic mice expressing Cre recombinase under the control of the endogenous cardiomyocyte-specific β-myosin heavy chain (β-MHC) promoter to generate RhoA
βMHC-cre
mice. Deletion of RhoA with β-MHC-Cre produced viable adults with > 85% loss of RhoA protein in the heart, without altering the basic architecture and function of the heart compared to control hearts, at both 2 and 8 months of age. However, subjecting RhoA
βMHC-cre
hearts to 2 weeks of TAC resulted in marked increase in cardiac hypertrophy (HW/BW (mg/g): 9.5 ± 0.3 for RhoA
βMHC-cre
versus 7.7 ± 0.4 for RhoA
flx/flx
; and cardiomyocyte size (mm
2
): 407 ± 21 for RhoA
βMHC-cre
versus 262 ± 8 for RhoA
flx/flx
; n ≥ 8 per group; p<0.01) and a significantly increased fibrotic response. Moreover, RhoA
βMHC-cre
hearts transitioned more quickly into heart failure whereas control mice maintained proper cardiac function (fractional shortening (%): 23.3 ± 1.2 for RhoA
βMHC-cre
versus 29.3 ± 1.2 for RhoA
flx/flx
; n ≥ 8 per group; p<0.01; 12 weeks after TAC). The latter was further associated with a significant increase in lung weight normalized to body weight and re-expression of the cardiac fetal gene program. In addition, these mice also displayed greater cardiac hypertrophy in response to 2 weeks of angiotensinII/phenylephrine infusion.
Conclusion.
These data identify RhoA as an antihypertrophic molecular switch in the mouse heart.
Collapse
Affiliation(s)
| | | | - Allen J York
- Cincinnati Children's Hosp Med Cntr, Cincinnati, OH
| | - Yi Zheng
- Cincinnati Children's Hosp Med Cntr, Cincinnati, OH
| | | |
Collapse
|
27
|
Xiang SY, Miyamoto S, Vanhoutte D, Molkentin JD, Dorn GW, Heller Brown J. Abstract P290: RhoA Protects Against Myocardial Ischemia/Reperfusion Injury. Circ Res 2011. [DOI: 10.1161/res.109.suppl_1.ap290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The small GTPase RhoA has established effects on cytoskeletal dynamics and gene expression but its role in regulating cardiac physiology and disease remains elusive. To characterize the in vivo role of RhoA signaling in cardiomyocytes, we generated conditional cardiac-specific RhoA transgenic mice (CA-RhoA) with 2–5 fold increases in RhoA activation in the adult heart. CA-RhoA mice show no overt cardiomyopathy but when challenged by in vivo or ex vivo I/R, these mice exhibit strikingly increased tolerance to injury. Compared to control mice, myocardial infarct size in CA-RhoA mice is reduced by 60–70% (20% vs. 50%, ex vivo; 10% vs. 37%, in vivo) and recovery of contractile function is significantly improved. Protein kinase D (PKD) is robustly activated in CA-RhoA hearts and inhibiting PKD reverses the cardioprotection afforded by RhoA. Both RhoA and PKD are also activated during I/R and blocking PKD augments I/R injury in WT mouse hearts. To further confirm that RhoA and PKD play a protective role during I/R, cardiac-specific RhoA knockout mice generated in the Molkentin laboratory were tested and demonstrated to show decreased tolerance to I/R injury, manifests as increased infarct size (42% vs. 23%) and lactate dehydrogenase release relative to control mice. This was accompanied by attenuated PKD activation during I/R. Taken together, our data indicates that RhoA signaling in adult cardiomyocytes promotes survival and reveals an unexpected role of PKD as a downstream mediator of RhoA and on cardioprotection against I/R.
Collapse
|
28
|
Affiliation(s)
- Davy Vanhoutte
- From the Department of Cardiovascular Diseases (D.V., S.H.), KU Leuven, Leuven, Belgium; Molecular Cardiovascular Biology (D.V.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Center for Heart Failure Research (S.H.), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands
| | - Stephane Heymans
- From the Department of Cardiovascular Diseases (D.V., S.H.), KU Leuven, Leuven, Belgium; Molecular Cardiovascular Biology (D.V.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Center for Heart Failure Research (S.H.), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands
| |
Collapse
|
29
|
Xiang SY, Vanhoutte D, Del Re DP, Purcell NH, Ling H, Banerjee I, Bossuyt J, Lang RA, Zheng Y, Matkovich SJ, Miyamoto S, Molkentin JD, Dorn GW, Brown JH. RhoA protects the mouse heart against ischemia/reperfusion injury. J Clin Invest 2011; 121:3269-76. [PMID: 21747165 DOI: 10.1172/jci44371] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2011] [Accepted: 05/18/2011] [Indexed: 12/24/2022] Open
Abstract
The small GTPase RhoA serves as a nodal point for signaling through hormones and mechanical stretch. However, the role of RhoA signaling in cardiac pathophysiology is poorly understood. To address this issue, we generated mice with cardiomyocyte-specific conditional expression of low levels of activated RhoA (CA-RhoA mice) and demonstrated that they exhibited no overt cardiomyopathy. When challenged by in vivo or ex vivo ischemia/reperfusion (I/R), however, the CA-RhoA mice exhibited strikingly increased tolerance to injury, which was manifest as reduced myocardial lactate dehydrogenase (LDH) release and infarct size and improved contractile function. PKD was robustly activated in CA-RhoA hearts. The cardioprotection afforded by RhoA was reversed by PKD inhibition. The hypothesis that activated RhoA and PKD serve protective physiological functions during I/R was supported by several lines of evidence. In WT mice, both RhoA and PKD were rapidly activated during I/R, and blocking PKD augmented I/R injury. In addition, cardiac-specific RhoA-knockout mice showed reduced PKD activation after I/R and strikingly decreased tolerance to I/R injury, as shown by increased infarct size and LDH release. Collectively, our findings provide strong support for the concept that RhoA signaling in adult cardiomyocytes promotes survival. They also reveal unexpected roles for PKD as a downstream mediator of RhoA and in cardioprotection against I/R.
Collapse
Affiliation(s)
- Sunny Yang Xiang
- Department of Pharmacology, UCSD, San Diego, California 92093-0636, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Chaubey S, Murdoch CE, Ivetic A, Yu B, Vanhoutte D, Heymans S, Brewer A, Shah AM. 138 Cell-specific role of NOX2 NADPH oxidase in development of angiotensin ii-induced cardiac fibrosis in vivo. Heart 2011. [DOI: 10.1136/heartjnl-2011-300198.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Loges S, Schmidt T, Tjwa M, van Geyte K, Lievens D, Lutgens E, Vanhoutte D, Borgel D, Plaisance S, Hoylaerts M, Luttun A, Dewerchin M, Carmeliet P. Abstract 1353: Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-1353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Growth arrest-specific gene 6 (Gas6) binds to the TAM family of receptor tyrosine kinases (TAMRs) and exerts pleiotropic functions in health and disease. TAMRs, in particular Axl, have transforming properties, and are highly expressed in human tumor cells. In contrast, little is known about the role of Gas6 in cancer. Previous studies indicate that Gas6 stimulates proliferation of cancer cells in vitro and that it is present in human tumor tissue. By using Gas6-deficient mice, we explored the role of Gas6 in tumor biology in vivo in detail and here unravel a previously unknown mechanism, how malignant cells educate infiltrating leukocytes, in particular macrophages, to upregulate Gas6 and as such promote their growth. By analyzing Gas6 expression, we found that in murine syngeneic tumor models (colonic CT26, pancreatic Panc02 and breast 4T1 tumors) Gas6 is exclusively expressed in host cells, most notably in tumor-infiltrating leukocytes, and to a lesser extent in tumor endothelial cells, but was beyond threshold of detection in tumor cells. Investigation of Gas6 expression in different intratumoral leukocyte subfractions (macrophages, monocytes, granulocytes, T-cells, B-cells, dendritic cells, NK cells) revealed highest Gas6 expression in tumor-associated macrophages (TAMs) and dendritic cells. Importantly, by comparing Gas6 expression in TAMs to resident tissue macrophages (isolated from spleen, lung and peritoneum), we found that tumors specifically educate TAMs to upregulate Gas6, which is mediated by IL-10. To analyze a potential impact of Gas6 on tumor progression, we studied growth of different tumor models (see above) in Gas6-/- mice, and found impaired tumor growth and metastasis in all studied models, including one resistant to VEGF inhibitors (lymphoma EL4), by 35-55%. Phenotypic analyses of tumors grown in wt mice in comparison to Gas6-deficient mice revealed reduced proliferation of tumor cells in Gas6-/- hosts. Angiogenesis, lymphangiogenesis, apoptosis and intra-tumoral coagulation were similar in both genotypes. Based on these findings we put forward the hypothesis that tumors educate infiltrating leukocytes to upregulate Gas6, which stimulates their growth. To functionally proof this concept, we performed cross-over bone marrow transplantation (BMT) studies in 3 different tumor models. These experiments revealed that transplantation of wt bone marrow into Gas6-/- hosts rescues impaired tumor growth, conversely transplantation of Gas6-/- bone marrow into wt hosts phenocopies decreased tumor growth in Gas6-/- mice. Hence, bone marrow-derived cells indeed deliver growth-promoting Gas6 into tumors, which stimulates their growth. This concept was further underscored by strongly reduced capability of Gas6-/- TAMs to stimulate proliferation of tumor cells compared to wt TAMs. In summary, our studies identify Gas6 as potential novel target in cancer.
Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1353.
Collapse
Affiliation(s)
| | | | | | | | - Dirk Lievens
- 2Cardiovascular Research Institute Maastricht, Maastricht, Netherlands
| | - Esther Lutgens
- 2Cardiovascular Research Institute Maastricht, Maastricht, Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Murdoch CE, Brewer A, Zhang M, Vanhoutte D, Heymans S, Shah AM. 009 Endothelial-specific overexpression of Nox2 enhances angiotensin II-induced cardiac dysfunction and fibrosis. Heart 2010. [DOI: 10.1136/hrt.2009.191049i] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
33
|
Schellings MWM, Vanhoutte D, van Almen GC, Swinnen M, Leenders JJG, Kubben N, van Leeuwen REW, Hofstra L, Heymans S, Pinto YM. Syndecan-1 amplifies angiotensin II-induced cardiac fibrosis. Hypertension 2010; 55:249-56. [PMID: 20048198 DOI: 10.1161/hypertensionaha.109.137885] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Syndecan-1 (Synd1) is a transmembrane heparan sulfate proteoglycan that functions as a coreceptor for various growth factors and modulates signal transduction. The present study investigated whether Synd1, by affecting growth factor signaling, may play a role in hypertension-induced cardiac fibrosis and dysfunction. Expression of Synd1 was increased significantly in mouse hearts with angiotensin II-induced hypertension, which was spatially related to cardiac fibrosis. Angiotensin II significantly impaired fractional shortening and induced cardiac fibrosis in wild-type mice, whereas these effects were blunted in Synd1-null mice. Angiotensin II significantly increased cardiac expression of connective tissue growth factor and collagen type I and III in wild-type mice, which was blunted in Synd1-null mice. These findings were confirmed in vitro, where angiotensin II induced the expression of both connective tissue growth factor and collagen I in fibroblasts. The absence of Synd1 in either Synd1-null fibroblasts, after knockdown of Synd1 by short hairpin RNA, or after inhibition of heparan sulfates by protamine attenuated this increase, which was associated with reduced phosphorylation of Smad2. In conclusion, loss of Synd1 reduces cardiac fibrosis and dysfunction during angiotensin II-induced hypertension.
Collapse
Affiliation(s)
- Mark W M Schellings
- Department of Cardiology, Cardiovascular Research Institute Maastricht, University Hospital Maastricht, Maastricht, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Swinnen M, Vanhoutte D, Van Almen GC, Hamdani N, Schellings MWM, D'hooge J, Van der Velden J, Weaver MS, Sage EH, Bornstein P, Verheyen FK, VandenDriessche T, Chuah MK, Westermann D, Paulus WJ, Van de Werf F, Schroen B, Carmeliet P, Pinto YM, Heymans S. Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation 2009; 120:1585-97. [PMID: 19805649 DOI: 10.1161/circulationaha.109.863266] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
BACKGROUND The progressive shift from a young to an aged heart is characterized by alterations in the cardiac matrix. The present study investigated whether the matricellular protein thrombospondin-2 (TSP-2) may affect cardiac dimensions and function with physiological aging of the heart. METHODS AND RESULTS TSP-2 knockout (KO) and wild-type mice were followed up to an age of 60 weeks. Survival rate, cardiac function, and morphology did not differ at a young age in TSP-2 KO compared with wild-type mice. However, >55% of the TSP-2 KO mice died between 24 and 60 weeks of age, whereas <10% of the wild-type mice died. In the absence of TSP-2, older mice displayed a severe dilated cardiomyopathy with impaired systolic function, increased cardiac dilatation, and fibrosis. Ultrastructural analysis revealed progressive myocyte stress and death, accompanied by an inflammatory response and replacement fibrosis, in aging TSP-2 KO animals, whereas capillary or coronary morphology or density was not affected. Importantly, adeno-associated virus-9 gene-mediated transfer of TSP-2 in 7-week-old TSP-2 KO mice normalized their survival and prevented dilated cardiomyopathy. In TSP-2 KO animals, age-related cardiomyopathy was accompanied by increased matrix metalloproteinase-2 and decreased tissue transglutaminase-2 activity, together with impaired collagen cross-linking. At the cardiomyocyte level, TSP-2 deficiency in vivo and its knockdown in vitro decreased the activation of the Akt survival pathway in cardiomyocytes. CONCLUSIONS TSP-2 expression in the heart protects against age-dependent dilated cardiomyopathy.
Collapse
Affiliation(s)
- Melissa Swinnen
- Center for Heart Failure Research, CARIM, Maastricht University, Maastricht, the Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Schellings MWM, Vanhoutte D, Swinnen M, Cleutjens JP, Debets J, van Leeuwen REW, d'Hooge J, Van de Werf F, Carmeliet P, Pinto YM, Sage EH, Heymans S. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. ACTA ACUST UNITED AC 2008; 206:113-23. [PMID: 19103879 PMCID: PMC2626676 DOI: 10.1084/jem.20081244] [Citation(s) in RCA: 149] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The matricellular protein SPARC (secreted protein, acidic and rich in cysteine, also known as osteonectin) mediates cell–matrix interactions during wound healing and regulates the production and/or assembly of the extracellular matrix (ECM). This study investigated whether SPARC functions in infarct healing and ECM maturation after myocardial infarction (MI). In comparison with wild-type (WT) mice, animals with a targeted inactivation of SPARC exhibited a fourfold increase in mortality that resulted from an increased incidence of cardiac rupture and failure after MI. SPARC-null infarcts had a disorganized granulation tissue and immature collagenous ECM. In contrast, adenoviral overexpression of SPARC in WT mice improved the collagen maturation and prevented cardiac dilatation and dysfunction after MI. In cardiac fibroblasts in vitro, reduction of SPARC by short hairpin RNA attenuated transforming growth factor β (TGF)–mediated increase of Smad2 phosphorylation, whereas addition of recombinant SPARC increased Smad2 phosphorylation concordant with increased Smad2 phosphorylation in SPARC-treated mice. Importantly, infusion of TGF-β rescued cardiac rupture in SPARC-null mice but did not significantly alter infarct healing in WT mice. These findings indicate that local production of SPARC is essential for maintenance of the integrity of cardiac ECM after MI. The protective effects of SPARC emphasize the potential therapeutic applications of this protein to prevent cardiac dilatation and dysfunction after MI.
Collapse
Affiliation(s)
- Mark W M Schellings
- Center for Heart Failure Research, Cardiovascular Research Institute Maastricht, University Hospital Maastricht, 6229 HX Maastricht, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
|
37
|
Vanhoutte D, Schellings MWM, Götte M, Swinnen M, Herias V, Wild MK, Vestweber D, Chorianopoulos E, Cortés V, Rigotti A, Stepp MA, Van de Werf F, Carmeliet P, Pinto YM, Heymans S. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation 2007; 115:475-82. [PMID: 17242279 DOI: 10.1161/circulationaha.106.644609] [Citation(s) in RCA: 105] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The cell-associated proteoglycan syndecan-1 (Synd1) closely regulates inflammation and cell-matrix interactions during wound healing and tumorigenesis. The present study investigated whether Synd1 may also regulate cardiac inflammation, matrix remodeling, and function after myocardial infarction (MI). METHODS AND RESULTS First, we showed increased protein and mRNA expression of Synd1 from 24 hours on, reaching its maximum at 7 days after MI and declining thereafter. Targeted deletion of Synd1 resulted in increased inflammation and accelerated, yet functionally adverse, infarct healing after MI. In concordance, adenoviral gene expression of Synd1 protected against exaggerated inflammation after MI, mainly by reducing transendothelial adhesion and migration of leukocytes, as shown in vitro. Increased inflammation in the absence of Synd1 resulted in increased monocyte chemoattractant protein-1 expression, increased activity of matrix metalloproteinase-2 and -9, and decreased activity of tissue transglutaminase, associated with increased collagen fragmentation and disorganization. Exaggerated inflammation and adverse matrix remodeling in the absence of Synd1 increased cardiac dilatation and impaired systolic function, whereas gene overexpression of Synd1 reduced inflammation and protected against cardiac dilatation and failure. CONCLUSIONS Increased expression of Synd1 in the infarct protects against exaggerated inflammation and adverse infarct healing, thereby reducing cardiac dilatation and dysfunction after MI in mice.
Collapse
Affiliation(s)
- Davy Vanhoutte
- Experimental and Molecular Cardiology/CARIM, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Heymans S, Vanhoutte D, Pinto Y. P.025 ABSENCE OF SYNDECAN-1 RESULTS IN INCREASED INFARCT HEALING AND DEPRESSED CARDIAC FUNCTION AFTER ACUTE MYOCARDIAL INFARCTION. Artery Res 2007. [DOI: 10.1016/s1872-9312(07)70048-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
39
|
Heymans S, Pauschinger M, De Palma A, Kallwellis-Opara A, Rutschow S, Swinnen M, Vanhoutte D, Gao F, Torpai R, Baker AH, Padalko E, Neyts J, Schultheiss HP, Van de Werf F, Carmeliet P, Pinto YM. Inhibition of Urokinase-Type Plasminogen Activator or Matrix Metalloproteinases Prevents Cardiac Injury and Dysfunction During Viral Myocarditis. Circulation 2006; 114:565-73. [PMID: 16880329 DOI: 10.1161/circulationaha.105.591032] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Acute viral myocarditis is an important cause of cardiac failure in young adults for which there is no effective treatment apart from general heart failure therapy. The present study tested the hypothesis that increased expression of the proteinases urokinase-type plasminogen activator (uPA) and matrix metalloproteinases (MMPs) is implicated in cardiac inflammation, injury, and subsequent failure during Coxsackievirus-B3 (CVB3)–induced myocarditis.
Methods and Results—
First, we showed increased expression and activity of uPA and MMP-9 in wild-type mice at 7 days of CVB3-induced myocarditis. Targeted deletion of uPA, which resulted in reduced MMP activity and cytokine expression or inhibition of MMPs by adenoviral gene overexpression of tissue inhibitor of metalloproteinases-1, decreased cardiac inflammation and reduced myocardial necrosis at 7 days and decreased cardiac fibrosis at 35 days after CVB3 infection. Importantly, loss of uPA or MMP activity prevented CVB3-induced cardiac dilatation and dysfunction, as determined by serial echocardiography.
Conclusions—
Loss of uPA or MMP activity reduces the cardiac inflammatory response after CVB3 infection, thereby protecting against cardiac injury, dilatation, and failure during CVB3-induced myocarditis.
Collapse
Affiliation(s)
- Stephane Heymans
- Molecular and Experimental Cardiology, CARIM, Department of Cardiology, P. Debyelaan 25, PO Box 5800, 6202AZ Maastricht, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 2005; 69:604-13. [PMID: 16360129 DOI: 10.1016/j.cardiores.2005.10.002] [Citation(s) in RCA: 192] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2005] [Revised: 10/03/2005] [Accepted: 10/04/2005] [Indexed: 11/29/2022] Open
Abstract
The post-myocardial infarction wound repair process involves temporarily overlapping phases that include inflammation, formation of granulation tissue, scar formation, and overall left ventricle (LV) remodelling. The myocardial extracellular matrix (ECM) plays an important role in maintaining the structural and functional integrity of the heart and is centrally involved in wound repair post-myocardial infarction (MI). The main proteolytic system involved in the degradation of the ECM in the heart is the matrix metalloproteinase (MMPs) system. The present review will focus on the importance of the unique temporal and spatial window of MMPs and their inhibitors (TIMPs) within the different wound healing phases post-MI. It summarizes (1) the MMP/TIMP levels at different time points post-MI, (2) the alterations seen in post-MI healing in genetically modified mice, and (3) the effects and limitations of therapeutic MMP-inhibition post-MI.
Collapse
Affiliation(s)
- Davy Vanhoutte
- Molecular and Vascular Biology and Center for Transgene Technology and Gene Therapy, University of Leuven, Belgium
| | | | | | | |
Collapse
|